Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.
IPO Year:
Exchange: NASDAQ
Website: humanigen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2022 | $13.00 → $2.00 | Buy → Neutral | ROTH Capital |
| 7/13/2022 | $30.00 → $2.00 | Overweight → Neutral | Cantor Fitzgerald |
| 7/13/2022 | Buy → Neutral | H.C. Wainwright | |
| 9/10/2021 | $9.00 | Buy → Hold | Jefferies |
| 9/9/2021 | Outperform → Neutral | Credit Suisse | |
| 9/9/2021 | $36.00 → $28.00 | Buy | H.C. Wainwright |
| 9/9/2021 | Neutral → Underweight | JP Morgan | |
| 8/13/2021 | $25.00 → $24.00 | Outperform | Credit Suisse |
| 8/10/2021 | $37.00 → $32.00 | Buy | Roth Capital |
ROTH Capital downgraded Humanigen from Buy to Neutral and set a new price target of $2.00 from $13.00 previously
Cantor Fitzgerald downgraded Humanigen from Overweight to Neutral and set a new price target of $2.00 from $30.00 previously
H.C. Wainwright downgraded Humanigen from Buy to Neutral
Jefferies downgraded Humanigen from Buy to Hold and set a new price target of $9.00
Credit Suisse downgraded Humanigen from Outperform to Neutral
H.C. Wainwright reiterated coverage of Humanigen with a rating of Buy and set a new price target of $28.00 from $36.00 previously
JP Morgan downgraded Humanigen from Neutral to Underweight
Credit Suisse reiterated coverage of Humanigen with a rating of Outperform and set a new price target of $24.00 from $25.00 previously
Roth Capital reiterated coverage of Humanigen with a rating of Buy and set a new price target of $32.00 from $37.00 previously
Credit Suisse initiated coverage of Humanigen with a rating of Outperform and set a new price target of $28.00
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that it will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications and provide a corporate update at 8am EST on December 2, 2021. The peer-reviewed paper in The Lancet Respiratory Medicine is available via the follow link: https://doi.org/10.1016/S2213-2600(21)00494-X The associated comment in The Lancet Respiratory Medicine is available via the following link: https://doi.org/10.1016/S2213-2600(21)00539-7 Details about how to access the conference call and webcast are pr
SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)
SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)
SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)
SC 13G/A - HUMANIGEN, INC (0001293310) (Subject)
SC 13G - HUMANIGEN, INC (0001293310) (Subject)
SC 13G - HUMANIGEN, INC (0001293310) (Subject)
SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)
SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)
SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)
SC 13D/A - HUMANIGEN, INC (0001293310) (Subject)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
4 - HUMANIGEN, INC (0001293310) (Issuer)
8-K - HUMANIGEN, INC (0001293310) (Filer)
25-NSE - HUMANIGEN, INC (0001293310) (Subject)
8-K - HUMANIGEN, INC (0001293310) (Filer)
NT 10-Q - HUMANIGEN, INC (0001293310) (Filer)
8-K - HUMANIGEN, INC (0001293310) (Filer)
10-Q - HUMANIGEN, INC (0001293310) (Filer)
10-K/A - HUMANIGEN, INC (0001293310) (Filer)
8-K - HUMANIGEN, INC (0001293310) (Filer)
8-K - HUMANIGEN, INC (0001293310) (Filer)
10-K - HUMANIGEN, INC (0001293310) (Filer)
CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix evaluable subjects, including those with high risk CMML, demonstrated clinical benefit at three months follow-upLenzilumab appears to be well-toleratedShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - April 14, 2023) - Humanigen, Inc. (NASDAQ:HGEN), Humanigen Australia Pty Ltd, (Humanigen) and the South Australian Health and Medical Research Institute (SAHMRI) today presented (poster CT085/13); the design and baseline results of the Precision Approach to Chronic Myelomono
Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the third quarter and nine months ended September 30, 2022.In July 2022, the company announced a strategic realignment of its pipeline, resources and regulatory strategy. The company is accelerating the development of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare blood cancer, for which the PREACH-M study is already underway. The company is also contin
Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced that Cameron Durrant, MD, MBA, Chairman & CEO, will give a corporate presentation at 11:25am EST (4:25pm local time) at the Jefferies London Healthcare Conference taking place on November 17, 2022. Dr. Durrant will provide an update on the clinical development of lenzilumab, Ifabotuzumab and HGEN005.A livestream will be available and a webcast link to a recording of the event will be posted to the "Events and Presentations" section of Humanige
Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced it has engaged SC&H Capital, an affiliate of SC&H Group, to advise Humanigen on exploration of strategic options. SC&H is an investment banking and advisory firm providing merger and acquisition (M&A), financial restructuring and related business advisory solutions to emerging and growing companies. Cameron Durrant, CEO Humanigen, said, "Our engagement of SC&H represents a continuation of our strategic realignment of our clinical development p
Additional Clinical Sites Expected to Enroll CMML Patients in AustraliaShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - September 12, 2022) - Humanigen, Inc. (NASDAQ:HGEN), Humanigen Australia Pty Ltd, ("Humanigen") and the South Australian Health and Medical Research Institute ("SAHMRI") today announced an expansion of the ongoing development Precision Approach to Chronic Myelomonocytic Leukemia ("PREACH-M") study of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a rare blood cancer, in patients with NRAS, KRAS, and CBL genetic mutations. The PREACH-M study will expand from the first two sites at the Royal Adelaide Hospital in Adelaide, Southern Australia a
Short Hills, New Jersey--(Newsfile Corp. - September 7, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab ("LENZ®"), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor ("GM-CSF"), today announced presentation and participation in two healthcare focused investor conferences in September 2022. Details of the presentation and panel participation are as follows:H.C. Wainwright 24th Annual Global Investment ConferencePresentation date: September 12, 2022Presentation time: 4:00 ETLocation: New York City, New YorkWebcast link: https://journey.ct.events/view/d74dea38-b7c3-4aef-922
Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors. Mr. Boehm will serve on Omega's audit and compensation committees. "Rainer's growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase o
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022. "We have made excellent progress on the strategic realignment announced in July. We have increased the number of sites for the PREACH-M study in Australia of lenzilumab in chronic myelomonocytic leukemia (‘CMML'), a rare blood cancer, and have interest from top oncology centers in the United States. We are on track to enroll the first patient in the RATinG study in the UK
Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo
Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today announced a strategic realignment of its pipeline and resources to achieve key clinical milestones. The Company plans to accelerate the development of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a rare blood cancer, for which the PREACH-M study is already underway. Humanigen will also advance its plan to study lenzilumab in acute graft versus host disease ("aGvHD") that occurs in patients underg
Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced the appointment of Rainer Boehm as an independent director to its Board of Directors. Mr. Boehm will serve on Omega's audit and compensation committees. "Rainer's growth-oriented perspective and global strategic management experience will be invaluable to Omega in this next phase o
Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations, effective immediately, reporting to Timothy E. Morris, COO/CFO of Humanigen. Mr. Trbovich brings to Humanigen 20 years of experience on Wall Street as a Managing Director and Senior Analyst at several leading investment banks including Janney Montgomery Scott, MLV & Co. (now part of B. Riley), C.E. Unterberg, Towbin (now part of C
Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab™, today announced the appointment of Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer, effective immediately, reporting to Dr. Cameron Durrant, CEO of Humanigen. Dr. Kilcoyne brings to Humanigen strong leadership experience from multinational pharmaceutical and biotechnology companies and a strong clinical background in both Internal Medicine and Public Health Medicine. His most recent leadership role was in AstraZeneca, where he served as Vice Pre
Humanigen (OTC:HGEN) has filed for bankruptcy likely as a result of the U.S. Food and Drug Administration’s (FDA) rejection of its COVID-19 drug, lenzilumab. The company, previously linked with disgraced pharmaceutical entrepreneur Martin Shkreli, reported unsecured debts of $44.1 million against assets of $521,000. The FDA’s refusal in 2021 to grant emergency-use authorization for lenzilumab significantly impacted Humanigen’s financial stability. Citing Henry Madrid, the Senior Vice President of Finance, the Wall Street Journal noted that the rejection was a key factor in the company’s financial troubles. The regulatory body concluded that the drug’s potential benefits did no
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.28% to 35,510.96 while the NASDAQ rose 0.91% to 14,187.05. The S&P 500, also rose, gaining, 0.48% to 4,576.60. Check This Out: Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying Leading and Lagging Sectors Materials shares climbed by 1.8% on Tuesday. In trading on Tuesday, real estate shares fell by 0.6%. Top Headline Verizon Communications Inc (NYSE:VZ) reported better-than-expected earnings for its second quarter. It clocked a sales decline of 3.5% year-on-year to $32.6 billion, missing the consensus of $33.3 billion. Ad
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 33.8% to $4.63 during Tuesday's regular session. Trading volume for Bullfrog AI Hldgs's stock is 42.6 million as of 13:30 EST. This is 8458.3% of its average full-day volume over the last 100 days. The company's market cap stands at $28.2 million. Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock rose 32.66% to $19.82. Trading volume for Kiniksa Pharmaceuticals's stock is 3.0 million as of 13:30 EST. This is 719.4% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 billion. As per the press release, Q2 earnings came out today. Galecto (NASDAQ:GLTO) shares rose 28.51% to $3.02. As of 13:30
Gainers Aurora Acquisition Corp. (NASDAQ:AURC) shares jumped 192% to $30.54. Inpixon (NASDAQ:INPX) gained 117% to $0.33 after the company agreed to merge with XTI Aircraft Company. Electra Battery Materials Corporation (NASDAQ:ELBM) shares shot up 71.5% to $2.11 after jumping 22% on Monday. Electra Battery Materials said its battery grade cobalt supply agreement with LG Energy Solution has been extended and expanded from terms initially announced in Sept. 2022. Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) shares gained 35.3% to $4.68 after the company announced US patent for novel prodrugs of mebendazole and their use in treating cancer. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) climb
On Tuesday, 56 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS). 9 Meters Biopharma (NASDAQ:NMTR) was the smallest company by market cap to set a new 52-week low. Humanigen (NASDAQ:HGEN)'s stock came under the most pressure, trading down 73.22% to reach a new 52-week low. NeuBase Therapeutics (NASDAQ:NBSE) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. On Tuesday, the following stocks set new 52-week lows: Apellis Pharmaceuticals (NASDAQ:APLS) stock drifted down 2.25% on Tuesday morning to hi
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 50 points on Tuesday. The Dow traded up 0.16% to 35,468.65 while the NASDAQ rose 0.60% to 14,142.63. The S&P 500, also rose, gaining, 0.27% to 4,566.98. Check This Out: Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying Leading and Lagging Sectors Materials shares climbed by 1.8% on Tuesday. In trading on Tuesday, financial shares fell by 0.4%. Top Headline General Electric Co (NYSE:GE) reported better-than-expected results for its second quarter. General Electric reported second-quarter FY23 revenues of $16.70 billion, an increase of 18% year-over-year, beating the consensus
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 70 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 35,393.00 while the NASDAQ rose 0.50% to 14,129.68. The S&P 500, also rose, gaining, 0.13% to 4,560.43. Check This Out: Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying Top Headline General Motors Company (NYSE:GM) reported better-than-expected earnings for its second quarter. General Motors posted quarterly earnings of $1.91 per share, beating market estimates of $1.85 per share. The company’s quarterly sales came in at $44.75 billion versus expectations of $42.64 billion. GM said it sees FY23 adju
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock moved upwards by 45.4% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $30.6 million. Enzo Biochem (NYSE:ENZ) shares rose 16.91% to $1.59. The market value of their outstanding shares is at $79.0 million. Aravive (NASDAQ:ARAV) shares moved upwards by 14.09% to $1.7. The market value of their outstanding shares is at $101.7 million. Novan (NASDAQ:NOVN) stock increased by 11.5% to $0.14. The market value of their outstanding shares is at $3.9 million. Biotricity (NASDAQ:BTCY) stock rose 10.72% to $3.51. The market value of their outstanding shares is at $30.7 million. Alpha Tau Medical (NASDAQ:DRTS) stock move
-8-K
Gainers Biofrontera (NASDAQ:BFRI) shares rose 52.2% to $0.67 during Monday's after-market session. At the close, Biofrontera's trading volume reached 2.3 million shares. This is 3249.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $17.8 million. Tivic Health Systems (NASDAQ:TIVC) stock rose 31.87% to $0.13. Today's trading volume for this security ended up closing at 5.9 million shares, which is 210.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $3.8 million. Cano Health (NYSE:CANO) stock increased by 25.6% to $1.57. Trading volume for this security closed at 2.1 million, accoun